Aptevo Therapeutics EBITDA 2014-2022 | APVO
Aptevo Therapeutics ebitda from 2014 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Aptevo Therapeutics Annual EBITDA
(Millions of US $) |
| 2021 |
$-20 |
| 2020 |
$-26 |
| 2019 |
$-39 |
| 2018 |
$-49 |
| 2017 |
$-51 |
| 2016 |
$-135 |
| 2015 |
$-58 |
| 2014 |
$-49 |
| 2013 |
$1 |
Aptevo Therapeutics Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$-5 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$-4 |
| 2021-06-30 |
$-5 |
| 2021-03-31 |
$-7 |
| 2020-12-31 |
$-6 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-6 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$-7 |
| 2019-09-30 |
$-11 |
| 2019-06-30 |
$-10 |
| 2019-03-31 |
$-11 |
| 2018-12-31 |
$-13 |
| 2018-09-30 |
$-12 |
| 2018-06-30 |
$-12 |
| 2018-03-31 |
$-13 |
| 2017-12-31 |
$-17 |
| 2017-09-30 |
$-9 |
| 2017-06-30 |
$-14 |
| 2017-03-31 |
$-11 |
| 2016-12-31 |
$-22 |
| 2016-09-30 |
$-89 |
| 2016-06-30 |
$-12 |
| 2016-03-31 |
$-12 |
| 2015-12-31 |
|
| 2015-09-30 |
$-12 |
| 2015-06-30 |
$-18 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.018B |
$0.012B |
|
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
|
